91ÖĆƬł§

Published on Market Research Reports® Inc. ()

Home > Global Generic Injectable Drugs Market Growth (Status and Outlook) 2025-2031

Global Generic Injectable Drugs Market Growth (Status and Outlook) 2025-2031

Publication ID: 
LPI01250101
Publication Date: 
January 8, 2025
Pages: 
109
Publisher: 
LPI
Countries: 
Global [1]
USD 3,660.00

Please choose the suitable license type from above. More details are given under tab "Report License Types" below.

Pharmaceutical Manufacturing [2]
Healthcare [3]
Pharma & Healthcare [4]
Description: 

The global Generic Injectable Drugs market size is predicted to grow from US$ 32060 million in 2025 to US$ 39710 million in 2031; it is expected to grow at a CAGR of 3.6% from 2025 to 2031.
Generic injectable drugs refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.
The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.
In the segment of generic sterile injectable drugs, the Hospira (Pfizer Inc.) is the largest player, and Fresenius Kabi is the second. Top two players hold a share about 27% in 2019. The US market is dominated by two players like Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma and Endo International PLC.
The “Generic Injectable Drugs Industry Forecast” looks at past sales and reviews total world Generic Injectable Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Generic Injectable Drugs sales for 2025 through 2031. With Generic Injectable Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Generic Injectable Drugs industry.
This Insight Report provides a comprehensive analysis of the global Generic Injectable Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Generic Injectable Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Generic Injectable Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Generic Injectable Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Generic Injectable Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Generic Injectable Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Small Molecule
Large Molecule
Segmentation by Application:
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Hospira (Pfizer Inc.)
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Auromedics
Sanofi
Gland Pharma
Endo International PLC

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents: 

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Generic Injectable Drugs Market Size (2020-2031)
2.1.2 Generic Injectable Drugs Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Generic Injectable Drugs by Country/Region (2020, 2024 & 2031)
2.2 Generic Injectable Drugs Segment by Type
2.2.1 Small Molecule
2.2.2 Large Molecule
2.3 Generic Injectable Drugs Market Size by Type
2.3.1 Generic Injectable Drugs Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Generic Injectable Drugs Market Size Market Share by Type (2020-2025)
2.4 Generic Injectable Drugs Segment by Application
2.4.1 Oncology
2.4.2 Anesthesia
2.4.3 Anti-Infectives
2.4.4 Parenteral Nutrition
2.4.5 Cardiovascular Diseases
2.5 Generic Injectable Drugs Market Size by Application
2.5.1 Generic Injectable Drugs Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Generic Injectable Drugs Market Size Market Share by Application (2020-2025)
3 Generic Injectable Drugs Market Size by Player
3.1 Generic Injectable Drugs Market Size Market Share by Player
3.1.1 Global Generic Injectable Drugs Revenue by Player (2020-2025)
3.1.2 Global Generic Injectable Drugs Revenue Market Share by Player (2020-2025)
3.2 Global Generic Injectable Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Generic Injectable Drugs by Region
4.1 Generic Injectable Drugs Market Size by Region (2020-2025)
4.2 Global Generic Injectable Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Generic Injectable Drugs Market Size Growth (2020-2025)
4.4 APAC Generic Injectable Drugs Market Size Growth (2020-2025)
4.5 Europe Generic Injectable Drugs Market Size Growth (2020-2025)
4.6 Middle East & Africa Generic Injectable Drugs Market Size Growth (2020-2025)
5 Americas
5.1 Americas Generic Injectable Drugs Market Size by Country (2020-2025)
5.2 Americas Generic Injectable Drugs Market Size by Type (2020-2025)
5.3 Americas Generic Injectable Drugs Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Generic Injectable Drugs Market Size by Region (2020-2025)
6.2 APAC Generic Injectable Drugs Market Size by Type (2020-2025)
6.3 APAC Generic Injectable Drugs Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Generic Injectable Drugs Market Size by Country (2020-2025)
7.2 Europe Generic Injectable Drugs Market Size by Type (2020-2025)
7.3 Europe Generic Injectable Drugs Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Generic Injectable Drugs by Region (2020-2025)
8.2 Middle East & Africa Generic Injectable Drugs Market Size by Type (2020-2025)
8.3 Middle East & Africa Generic Injectable Drugs Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Generic Injectable Drugs Market Forecast
10.1 Global Generic Injectable Drugs Forecast by Region (2026-2031)
10.1.1 Global Generic Injectable Drugs Forecast by Region (2026-2031)
10.1.2 Americas Generic Injectable Drugs Forecast
10.1.3 APAC Generic Injectable Drugs Forecast
10.1.4 Europe Generic Injectable Drugs Forecast
10.1.5 Middle East & Africa Generic Injectable Drugs Forecast
10.2 Americas Generic Injectable Drugs Forecast by Country (2026-2031)
10.2.1 United States Market Generic Injectable Drugs Forecast
10.2.2 Canada Market Generic Injectable Drugs Forecast
10.2.3 Mexico Market Generic Injectable Drugs Forecast
10.2.4 Brazil Market Generic Injectable Drugs Forecast
10.3 APAC Generic Injectable Drugs Forecast by Region (2026-2031)
10.3.1 China Generic Injectable Drugs Market Forecast
10.3.2 Japan Market Generic Injectable Drugs Forecast
10.3.3 Korea Market Generic Injectable Drugs Forecast
10.3.4 Southeast Asia Market Generic Injectable Drugs Forecast
10.3.5 India Market Generic Injectable Drugs Forecast
10.3.6 Australia Market Generic Injectable Drugs Forecast
10.4 Europe Generic Injectable Drugs Forecast by Country (2026-2031)
10.4.1 Germany Market Generic Injectable Drugs Forecast
10.4.2 France Market Generic Injectable Drugs Forecast
10.4.3 UK Market Generic Injectable Drugs Forecast
10.4.4 Italy Market Generic Injectable Drugs Forecast
10.4.5 Russia Market Generic Injectable Drugs Forecast
10.5 Middle East & Africa Generic Injectable Drugs Forecast by Region (2026-2031)
10.5.1 Egypt Market Generic Injectable Drugs Forecast
10.5.2 South Africa Market Generic Injectable Drugs Forecast
10.5.3 Israel Market Generic Injectable Drugs Forecast
10.5.4 Turkey Market Generic Injectable Drugs Forecast
10.6 Global Generic Injectable Drugs Forecast by Type (2026-2031)
10.7 Global Generic Injectable Drugs Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Generic Injectable Drugs Forecast
11 Key Players Analysis
11.1 Hospira (Pfizer Inc.)
11.1.1 Hospira (Pfizer Inc.) Company Information
11.1.2 Hospira (Pfizer Inc.) Generic Injectable Drugs Product Offered
11.1.3 Hospira (Pfizer Inc.) Generic Injectable Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Hospira (Pfizer Inc.) Main Business Overview
11.1.5 Hospira (Pfizer Inc.) Latest Developments
11.2 Fresenius Kabi
11.2.1 Fresenius Kabi Company Information
11.2.2 Fresenius Kabi Generic Injectable Drugs Product Offered
11.2.3 Fresenius Kabi Generic Injectable Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Fresenius Kabi Main Business Overview
11.2.5 Fresenius Kabi Latest Developments
11.3 Sandoz (Novartis)
11.3.1 Sandoz (Novartis) Company Information
11.3.2 Sandoz (Novartis) Generic Injectable Drugs Product Offered
11.3.3 Sandoz (Novartis) Generic Injectable Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Sandoz (Novartis) Main Business Overview
11.3.5 Sandoz (Novartis) Latest Developments
11.4 Hikma Pharmaceuticals PLC
11.4.1 Hikma Pharmaceuticals PLC Company Information
11.4.2 Hikma Pharmaceuticals PLC Generic Injectable Drugs Product Offered
11.4.3 Hikma Pharmaceuticals PLC Generic Injectable Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Hikma Pharmaceuticals PLC Main Business Overview
11.4.5 Hikma Pharmaceuticals PLC Latest Developments
11.5 Dr. Reddy’s Laboratories Ltd
11.5.1 Dr. Reddy’s Laboratories Ltd Company Information
11.5.2 Dr. Reddy’s Laboratories Ltd Generic Injectable Drugs Product Offered
11.5.3 Dr. Reddy’s Laboratories Ltd Generic Injectable Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Dr. Reddy’s Laboratories Ltd Main Business Overview
11.5.5 Dr. Reddy’s Laboratories Ltd Latest Developments
11.6 Grifols
11.6.1 Grifols Company Information
11.6.2 Grifols Generic Injectable Drugs Product Offered
11.6.3 Grifols Generic Injectable Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Grifols Main Business Overview
11.6.5 Grifols Latest Developments
11.7 Nichi-Iko Group (Sagent)
11.7.1 Nichi-Iko Group (Sagent) Company Information
11.7.2 Nichi-Iko Group (Sagent) Generic Injectable Drugs Product Offered
11.7.3 Nichi-Iko Group (Sagent) Generic Injectable Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Nichi-Iko Group (Sagent) Main Business Overview
11.7.5 Nichi-Iko Group (Sagent) Latest Developments
11.8 Teva Pharmaceutical
11.8.1 Teva Pharmaceutical Company Information
11.8.2 Teva Pharmaceutical Generic Injectable Drugs Product Offered
11.8.3 Teva Pharmaceutical Generic Injectable Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Teva Pharmaceutical Main Business Overview
11.8.5 Teva Pharmaceutical Latest Developments
11.9 Auromedics
11.9.1 Auromedics Company Information
11.9.2 Auromedics Generic Injectable Drugs Product Offered
11.9.3 Auromedics Generic Injectable Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Auromedics Main Business Overview
11.9.5 Auromedics Latest Developments
11.10 Sanofi
11.10.1 Sanofi Company Information
11.10.2 Sanofi Generic Injectable Drugs Product Offered
11.10.3 Sanofi Generic Injectable Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Sanofi Main Business Overview
11.10.5 Sanofi Latest Developments
11.11 Gland Pharma
11.11.1 Gland Pharma Company Information
11.11.2 Gland Pharma Generic Injectable Drugs Product Offered
11.11.3 Gland Pharma Generic Injectable Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Gland Pharma Main Business Overview
11.11.5 Gland Pharma Latest Developments
11.12 Endo International PLC
11.12.1 Endo International PLC Company Information
11.12.2 Endo International PLC Generic Injectable Drugs Product Offered
11.12.3 Endo International PLC Generic Injectable Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 Endo International PLC Main Business Overview
11.12.5 Endo International PLC Latest Developments
12 Research Findings and Conclusion

License Types: 

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

Ěý

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

Ěý

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL:/lpi/global-generic-injectable-drugs-market-growth-status-and-outlook-2025-2031

Links
[1] /countries/global[2] /pharmaceutical-manufacturing[3] /healthcare[4] /pharma-healthcare